medigraphic.com
ISSN 2448-8747 (Print)
Publicación cuatrimestral editada por la Secretaría de Salud Jalisco

2017, Number 3

<< Back Next >>

Sal Jal 2017; 4 (3)

El cáncer de próstata y un virus oncolítico como alternativa de tratamiento

Gutiérrez-Ortega RC, Sánchez-Soto JE, Gaona-Bernal J, Absalón-Constantino AE, Herrera-Rodríguez SE

Language: Spanish
References: 30
Page: 192-200
PDF size: 602.38 Kb.


ABSTRACT

Prostate cancer is the most common type of cancer found in males. More than 65% of prostate cancer cases are diagnosed in men over the age of 65, been this disease among the leading causes of death. Although this disease can be prevented or detected in early stages through annual exams such as: prostate specifi c antigen study, rectal examination and ultrasound. At date, the treatment for this type of cancer continues to be invasive and with multiple adverse eff ects such as: fatigue, hair loss, nausea, loss of appetite and consequently body weight. In recent years, research into cancer treatment has focused on making it more specific, sensitive and eff ective that has fewer adverse eff ects. In these sense, viruses have been used as an alternative to treat some types of cancer. In which oncolytic virotherapy based in virus has the characteristic by the specifi cally infection of tumor cell naturally or because of the adaptation of the virus to propagate in human tumor cells. In addition, these oncolytic viruses can be modified by genetic engineering to improve their oncolytic capacity and/or its selectivity for some cellular target. Th is review focus on the Newcastle virus disease and its potential in oncolytic virotherapy for treatment of prostate cancer, and to mention some genetic modifi cations that have been made to increase, monitor and evaluate its oncolytic activity.


REFERENCES

  1. Blattman J N, Greenberg P D. Cancer Immunotherapy : 305, 200– 205 (2004).

  2. Rezaei N, Aalaei-Andabili SH, Kaufman HL. in Cancer Immunology 1–8 (Springer Berlin Heidelberg, 2015). doi:10.1007/978-3-662-44006-3_1

  3. Langston DTK. Inherited predisposition to multiple myeloma. Th er. Adv. Hematol. 4, 291–297 (2013).

  4. White MC, et al. Age and cancer risk: a potentially modifi able relationship. Am. J. Prev. Med. 46, S7-15 (2014).

  5. Dorak MT, Karpuzoglu E. Gender diff erences in cancer susceptibility: an inadequately addressed issue. Front. Genet. 3, 268 (2012).

  6. Baquet CR, Mishra SI, Commiskey P, Ellison GL, DeShields M. Breast cancer epidemiology in blacks and whites: disparities in incidence, mortality, survival rates and histology. J. Natl. Med. Assoc. 100, 480–8 (2008).

  7. Anand P, et al. Cancer is a Preventable Disease that Requires Major Lifestyle Changes. Pharm. Res. 25, 2097–2116 (2008).

  8. Yuwanati M, Bhatnagar N, Mhaske S. Oncoviruses: An overview of oncogenic and oncolytic viruses. Oncobiology and Targets 2, 4 (2015).

  9. Becker WB, KL, HJ. El mundo de la cálula. (2006).

  10. Owen JA, P J, SS. Kuby Inmunología. (2014).

  11. Vogelstein B, et al. Cancer Genome Landscapes. Science (80-. ). 339, (2013).

  12. ¿Qué es el cáncer? - National Cancer Institute. Available at: https:// www.cancer.gov/espanol/cancer/naturaleza/que-es. (Accessed: 13th February 2017)

  13. Packer JR, Maitland NJ. Th e molecular and cellular origin of human prostate cancer. Biochim. Biophys. Acta - Mol. Cell Res. 1863, 1238– 1260 (2016).

  14. GLOBOCAN 2012. Available at: http://globocan.iarc.fr/old/bar_site. asp?selection=24191&title=Prostate&sex=1&statistic=2&populations= 6&window=1&grid=1&orientation=1&color1=5&color1e=& color2=4&color2e=&submit= Execute . (Accessed: 13th February 2017)

  15. GLOBOCAN 2012. Available at: http://globocan.iarc.fr/old/ bar_pop.asp?selection=126484&title=Mexico&sex=1&statistic= 0&window=1&grid=1&color1=5&color1e=&color2=4&color2e=& orientation=1&submit= Execute . (Accessed: 13th February 2017)

  16. Cáncer de próstata. Available at: http://www.imss.gob.mx/saluden- linea/cancer-prostata. (Accessed: 13th February 2017)

  17. Hassanipour-Azgomi S, et al. Incidence and mortality of prostate cancer and their relationship with the Human Development Index worldwide. Prostate Int. 4, 118–124 (2016).

  18. Shukla KK, et al. Recent scenario of microRNA as diagnostic and prognostic biomarkers of prostate cancer. Urol. Oncol. Semin. Orig. Investig. 1–10 (2016). doi:10.1016/j.urolonc.2016.10.019

  19. Mendhiratta N, Lee T, Prabhu V, Llukani E, Lepor H. 10-Year Mortality aft er Radical Prostatectomy for Localized Prostate Cancer in the Prostate-specifi c Antigen Screening Era. Urology 86, 783–788 (2015).

  20. Eager RM, Nemunaitis J. Clinical development directions in oncolytic viral therapy. Cancer Gene Ther. 18, 305–317 (2011).

  21. Engels FK, Verweij J. Docetaxel administration schedule: From fever to tears? A review of randomised studies. Eur. J. Cancer 41, 1117–1126 (2005).

  22. Aldrich JF, et al. Vaccines and immunotherapeutics for the treatment of malignant disease. Clin. Dev. Immunol. 2010, (2010).

  23. Wong HH, Lemoine NR, Wang Y. Oncolytic viruses for cancer therapy: Overcoming the obstacles. Viruses 2, 78–106 (2010).

  24. Mahoney DJ, Stojdl DF, Laird G. Virus Th erapy for Cancer. Sci. Am. 311, 54–59 (2014).

  25. Ledford H. Cancer-fi ghting viruses win approval. Nature 526, 622– 623 (2015).

  26. Fournier P, Schirrmacher V. Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host. Biology (Basel). 2, 936–75 (2013).

  27. ViralZone: Avulavirus. Available at: http://viralzone.expasy.org/ viralzone/all_by_species/84.html. (Accessed: 13th February 2017)

  28. Zhao L, Liu H. Newcastle disease virus: A promising agent for tumour immunotherapy. Clin. Exp. Pharmacol. Physiol. 39, 725– 730 (2012).

  29. Laurie SA, et al. A Phase 1 Clinical Study of Intravenous Administration of PV701, an Oncolytic Virus, Using Two-Step Desensitization. Clin. Cancer Res. 12, 2555–2562 (2006).

  30. Fournier P, Bian H, Szeberényi J, Schirrmacher V. Oncolytic Viruses. 797, 177–204 (2012).




2020     |     www.medigraphic.com